Analyze IONS

ShareShare on WhatsApp Share on Facebook Share on X

Equity Research · Deep diveIT-2026-IONS · 2026-07-29

Ionis Pharmaceuticals, Inc. (IONS)

HealthcareBiotechnologyNasdaqGSMarket cap $8.93B

$54.04

-2.28%

Analyst-style PDF, emailed within minutes

49/100

Mixed picture

Automated weighted score · not a recommendation

Price source: Yahoo · live price · as of 23:00 · Data: Yahoo · SEC EDGAR · FINRA · Wikidata

About the company

Market cap

$8.93B

P/E

—

Beta

0.37

Employees

1.40K

Sector: HealthcareIndustry: BiotechnologyExchange: NasdaqGSCountry: United StatesFounded: 1989 Website

What the company does

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Day range

$53.50$55.35

52-week range

$40.03$86.74

Price alert on IONS

Get an in-app and mobile alert every time IONS crosses a price you set.

Loading short data…

IONS · Chart

Loading chart…

SMA20 SMA50 SMA200

Charts by TradingView

Support & resistance

Key trading levels, by timeframe

Day

Swing

Computing levels…

The technical signal compass

Sign up free and build your own trading bot with full backtesting. Live bots, real-time alerts and the bot gallery — with a Pro subscription.

Free sign-up

Ionis Pharmaceuticals, Inc. (IONS) is trading around $54.04 (-2.28% on the last session). Its 52-week range runs from $40.03 to $86.74. Technically: 1 buy signals, 7 sell and 4 neutral. It belongs to the Healthcare sector (Biotechnology) and a 9B$ market cap. Data sourced from Yahoo · live price as of 23:00. This is data analysis only, not advice or a recommendation.

IONS stock FAQ

What is IONS's current price?

IONS is trading around $54.04 (-2.28%), as of 23:00 per Yahoo · live price.

What is IONS's 52-week price range?

Over the last 52 weeks IONS ranged between a $40.03 low and a $86.74 high.

Which sector does IONS belong to?

IONS belongs to the Healthcare sector, Biotechnology industry.

Disclosure & disclaimer: All information, scores, signals and trade plans on this site are produced by an automated algorithmic system and are based on technical and quantitative data only. They do not constitute investment advice, investment marketing or a recommendation to act, and are not a substitute for personal advice from a licensed professional that accounts for your needs and circumstances. We are not investment advisors. Trading securities involves substantial risk, up to the loss of your entire investment; every decision and action is your sole responsibility. i-trade and its operators bear no liability for any direct or indirect damage arising from reliance on this information.

0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ %€ ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇% ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 01 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 #$ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 €↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1

Building the strategy

IONS stock FAQ

What is IONS's current price?

IONS is trading around $54.04 (-2.28%), as of 23:00 per Yahoo · live price.

What is IONS's 52-week price range?

Over the last 52 weeks IONS ranged between a $40.03 low and a $86.74 high.

Which sector does IONS belong to?

IONS belongs to the Healthcare sector, Biotechnology industry.

Analyze IONS

Ionis Pharmaceuticals, Inc. (IONS)

About the company

IONS · Chart

Support & resistance

The technical signal compass

IONS stock FAQ

Ionis Pharmaceuticals, Inc. (IONS)

About the company

IONS · Chart

Support & resistance

The technical signal compass

IONS stock FAQ

Income statement analysis

Institutional & insider data

Full analyst coverage